Fasenra Approved in EU for Treatment of Severe Eosinophilic Asthma
Asthma, News
The European Commission has approved Fasenra (benralizumab) as an add-on maintenance treatment in patients with severe eosinophilic asthma. The approval, announced by therapy developer AstraZeneca and its global research and development arm, MedImmune, follows FDA approval of ... Read more